- $1.12bn
- $392.40m
- $635.76m
- 84
- 30
- 51
- 55
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 184 | 294 | 415 | 524 | 636 |
Cost of Revenue | |||||
Gross Profit | 94.8 | 155 | 249 | 331 | 330 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 233 | 360 | 558 | 701 | 781 |
Operating Profit | -48.4 | -66.6 | -143 | -177 | -146 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -46 | -65.3 | -143 | -171 | -111 |
Provision for Income Taxes | |||||
Net Income After Taxes | -46.7 | -66.8 | -145 | -175 | -117 |
Net Income Before Extraordinary Items | |||||
Net Income | -46.7 | -66.8 | -145 | -175 | -117 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -46.7 | -66.8 | -145 | -175 | -117 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.359 | -0.513 | -1.28 | -1.14 | -0.779 |
Dividends per Share |